{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T23:35:15Z","timestamp":1793230515181,"version":"4.5.0"},"reference-count":67,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2007,5,1]],"date-time":"2007-05-01T00:00:00Z","timestamp":1177977600000},"content-version":"vor","delay-in-days":1856,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Cellular Molecular Medi"],"published-print":{"date-parts":[[2002,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Thalidomide is a glutamic acid derivative initially introduced as a sedative hypnotic nearly forty years ago. It was withdrawn following numerous reports linking it to a characteristic pattern of congenital abnormalities in babies born to mothers who used the drug for morning sickness. It has gradually been re\u2010introduced into clinical practice over the past two decades, albeit under strict regulation, since it was found to be useful in the management of erythema nodosum leprosum and HIV wasting syndrome. Recognition of its anti\u2010angiogenic effect led to its evaluation in the treatment of various malignancies, where angiogenesis has been shown to play an important role. Numerous clinical trials done over the past four years have confirmed the significant anti\u2010myeloma activity of this drug. It has also shown promise in preliminary trials in the treatment of a variety of different malignant diseases. The mechanisms of its antineoplastic effects continue to be the focus of ongoing research. It has become clear that even though its anti angiogenic effects play a significant role in the anti\u2010tumor activity, there are other properties of this drug which are responsible as well. It also possesses anti\u2010TNF alpha activity, which has led to its evaluation in several inflammatory states. In this concise review, we briefly describe the historical background and pharmacological aspects of this drug. We have concisely reviewed the current knowledge regarding mechanisms of its anti\u2010neoplastic activity and the results of various clinical trials in oncology.<\/jats:p>","DOI":"10.1111\/j.1582-4934.2002.tb00184.x","type":"journal-article","created":{"date-parts":[[2007,5,1]],"date-time":"2007-05-01T12:15:54Z","timestamp":1178021754000},"page":"160-174","source":"Crossref","is-referenced-by-count":55,"title":["Thalidomide as an anti\u2010cancer agent"],"prefix":"10.1111","volume":"6","author":[{"given":"S.","family":"Kumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. E.","family":"Witzig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. V.","family":"Rajkumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2007,5]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(61)90927-8"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/0022-510X(76)90031-9"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/0012-1606(72)90126-1"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.91.9.4082"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1021\/js980172i"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.12.2797"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002280100320"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-2952(98)00046-X"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001813-199605000-00015"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197111182852108"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199512283332608"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1995.68"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/84.24.1875"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.1994.tb07122.x"},{"key":"e_1_2_1_16_2","first-page":"19a","article-title":"Bone marrow angiogenesis has prognostic value in multiple myeloma. An Eastern Cooperative Oncology Group Study","volume":"18","author":"Rajkumar S.V.","year":"1999","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_2_1_17_2","first-page":"728","article-title":"Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies","volume":"59","author":"Bellamy W.T.","year":"1999","journal-title":"Cancer Research"},{"key":"e_1_2_1_18_2","first-page":"303b","article-title":"Angiogenesis in myeloma: expression of basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and their receptors by neoplastic plasma cells","volume":"94","author":"Rajkumar S. V.","year":"1999","journal-title":"Blood"},{"key":"e_1_2_1_19_2","first-page":"800","article-title":"Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheral blood","volume":"85","author":"Raimondo F.","year":"2000","journal-title":"Haematologica"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V95.8.2630"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2001.00348.x"},{"key":"e_1_2_1_22_2","first-page":"363a","article-title":"Bone marrow (BM) angiogenesis in multiple myeloma (MM): effect of therapy and prognostic value","volume":"96","author":"Kumar S.","year":"2000","journal-title":"Blood"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.177.6.1675"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm960284r"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.187.11.1885"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.5935\/0305-7518.19850006"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.1995.tb05527.x"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/0162-3109(95)00050-X"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M100938200"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.9.2943"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0960-894X(02)00084-7"},{"key":"e_1_2_1_32_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.1.210"},{"key":"e_1_2_1_33_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199911183412102"},{"key":"e_1_2_1_34_2","first-page":"514a","article-title":"Long term follow up of 169 patients receiving a phase II trial of single agent thalidomide for advanced and refractory multiple myeloma (MM)","volume":"96","author":"Barlogie B.","year":"2000","journal-title":"Blood"},{"key":"e_1_2_1_35_2","doi-asserted-by":"publisher","DOI":"10.4065\/75.9.897"},{"key":"e_1_2_1_36_2","first-page":"162a","article-title":"Response Rate and Durablity of Response with Thalidomide Therapy for Relapsed Multiple Myeloma (MM)","volume":"98","author":"Rajkumar S.V.","year":"2001","journal-title":"Blood"},{"key":"e_1_2_1_37_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.2.492"},{"key":"e_1_2_1_38_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2000.01983.x"},{"key":"e_1_2_1_39_2","article-title":"Thalidomide (Thal) in the Treatment of Advanced Multiple Myeloma (MM). A Prospective Study of 120 Patients","volume":"98","author":"Grosbois B.","year":"2001","journal-title":"Blood"},{"key":"e_1_2_1_40_2","first-page":"404","article-title":"Thalidomide treatment of resistant or relapsed multiple myeloma patients","volume":"86","author":"Hus M.","year":"2001","journal-title":"Haematologica"},{"key":"e_1_2_1_41_2","first-page":"163a","article-title":"Low Dose Thalidomide Alone and in Combination: Long Term Follow\u2010Up","volume":"98","author":"Durie B.","year":"2001","journal-title":"Blood"},{"key":"e_1_2_1_42_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1011141009812"},{"key":"e_1_2_1_43_2","first-page":"168a","article-title":"Durable response to thalidomide in relapsed\/refractory multiple myeloma (MM)","volume":"96","author":"Raza S. N.","year":"2000","journal-title":"Blood"},{"issue":"408","key":"e_1_2_1_44_2","article-title":"Salvage therapy with thalidomide in patients with advanced relapsed\/refractory multiple myeloma","volume":"87","author":"Tosi P.","year":"2002","journal-title":"Haematologica"},{"key":"e_1_2_1_45_2","unstructured":"ScheyS. JonesR. W. CavenaghJ. JohnsonR. Thalidomide (T) in relapsed\/refractory multiple myeloma (MM): a UK Myeloma Forum study: 6 9 and 12\u2010month results Proc. ASCO: Abstract 1102 2002."},{"key":"e_1_2_1_46_2","article-title":"Consolidation Therapy of Multiple Myeloma with Thalidomide\u2010Dexamethasone after Intensive Chemotherapy","volume":"98","author":"Alexanian R.","year":"2001","journal-title":"Blood"},{"key":"e_1_2_1_47_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.16.3596"},{"key":"e_1_2_1_48_2","article-title":"A phase I\/II trial of thalidomide for patients with AL amyloidosis","volume":"98","author":"Seldin D.C.","year":"2001","journal-title":"Blood"},{"key":"e_1_2_1_49_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.3.834"},{"key":"e_1_2_1_50_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.4.958"},{"key":"e_1_2_1_51_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.03204.x"},{"key":"e_1_2_1_52_2","first-page":"746a","article-title":"Thalidomide in patients with myelofibrosis with myeloid metaplasia","volume":"96","author":"Barosi G.","year":"2000","journal-title":"Blood"},{"key":"e_1_2_1_53_2","article-title":"Phase II study of thalidomide in patients with recurrent Hodgkin's disease (HD) and non\u2010Hodgkin's lymphomas (NHL)","volume":"98","author":"Pro B.","year":"2001","journal-title":"Blood"},{"key":"e_1_2_1_54_2","first-page":"1888","article-title":"A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgenindependent prostate cancer","volume":"7","author":"Figg W. D.","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"e_1_2_1_55_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0093-7754(01)90157-5"},{"key":"e_1_2_1_56_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.14.2710"},{"key":"e_1_2_1_57_2","doi-asserted-by":"publisher","DOI":"10.1258\/0956462981921512"},{"key":"e_1_2_1_58_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.4.708"},{"key":"e_1_2_1_59_2","unstructured":"HwuW.J. KrownS.E. MenellJ.H. PanageasK.S. MerrellJ. QuinnC.J. ChapmanP.B. LivingstonP.O. WolchokJ.D. WilliamsL.J. HoughtonA.N. Temozolomide (TMZ) plus thalidomide in patients with advanced melanoma: a phase II trial Proc. ASCO: Abstract 1372 2002."},{"key":"e_1_2_1_60_2","first-page":"29","article-title":"Irinotecan and thalidomide in metastatic colorectal cancer","volume":"14","author":"Govindarajan R.","year":"2000","journal-title":"Oncology (Huntingt)"},{"key":"e_1_2_1_61_2","first-page":"775a","article-title":"A phase 1 study of oral CC5013, an immunomodulatory thalidomide (Thal) derivative, in patients with relapsed and refractory multiple myeloma (MM)","volume":"98","author":"Richardson P.G.","year":"2001","journal-title":"Blood"},{"key":"e_1_2_1_62_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2002.03443.x"},{"key":"e_1_2_1_63_2","doi-asserted-by":"publisher","DOI":"10.1054\/bjoc.1999.1004"},{"key":"e_1_2_1_64_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.13.2593"},{"key":"e_1_2_1_65_2","doi-asserted-by":"publisher","DOI":"10.1054\/bjoc.2001.2025"},{"key":"e_1_2_1_66_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.1.302"},{"key":"e_1_2_1_67_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1006414804835"},{"key":"e_1_2_1_68_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1012554328801"}],"container-title":["Journal of Cellular and Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1582-4934.2002.tb00184.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1582-4934.2002.tb00184.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,19]],"date-time":"2023-11-19T11:34:22Z","timestamp":1700393662000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1582-4934.2002.tb00184.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,4]]},"references-count":67,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2002,4]]}},"alternative-id":["10.1111\/j.1582-4934.2002.tb00184.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1582-4934.2002.tb00184.x","archive":["Portico"],"relation":{},"ISSN":["1582-1838","1582-4934"],"issn-type":[{"value":"1582-1838","type":"print"},{"value":"1582-4934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,4]]}}}